Fig. 1.
One-step secondary sarcoma development in sarcoma-induced pluripotent stem cells (iPSC) mice. a iPSC-like cells were generated from a murine clear-cell sarcoma (CCS) cell line (G1297) by introducing four reprogramming factors. Scale bars: 600 µm (upper), 300 µm (lower). b Array comparative genomic hybridization (CGH) analysis reveals that sarcoma-derived iPSC-like cells (clone G3) share identical chromosomal aberrations with parental sarcoma cells (G1297). c Candidate mutation sites in sarcoma cells (G1297) and sarcoma-derived iPSC-like cells (clone G3). Exome analysis reveals that more than 75% of candidate mutation sites in G1297 are overlapped with those in sarcoma-derived iPSC-like cells. d Sarcoma-derived iPSC-like cells contributed to adult chimeric mice after injection into blastocyst. e Secondary sarcoma development in sarcoma-iPSC mice treated with doxycycline (Dox). Secondary sarcoma preferentially arose in soft tissue. Left, center of chest and abdominal wall (Dox 1 week). Middle, subcutaneous tissue; right, abdominal fascia (Dox 4–5 weeks). f Secondary sarcoma developed at the subcutaneous layer (left) in sarcoma-iPSC mouse. Both iPSC G1- and G3-derived mice developed subcutaneous tumors. Histological analysis reveals that secondary sarcomas resemble primary CCS. EWS/ATF1 expression is detectable in secondary tumors by immunohistochemistry using hemagglutinin (HA) antibody. Scale bars: 100 µm. g Histology and Ki67-positive cell ratio of primary CCSs and secondary sarcomas. Scale bars: 50 µm. Primary CCSs were obtained from EWS/ATF1-induced embryonic stem cell (ESC) mice (Rosa-M2rtTA/Col1a1::tetO-EWS/ATF1-ires-mCherry), while secondary sarcomas were obtained from sarcoma-iPSC mice, which were generated with two independent iPSC clones (G1 and G3). The mean ± SD of six independent primary and secondary sarcomas are shown, respectively. No significant difference in the Ki67-positive cell ratio is observed between them (P = 0.4438, two-sided Student’s t test). h Tumor incidence within 2 weeks after Dox administration in chimeric mice generated with control ESCs, ETF-iPSCs (ear-tip fibroblast-iPSCs), and sarcoma-iPSCs. Sarcoma-iPSC mice developed secondary sarcomas at a higher incidence and shorter latency than other mice. Pink bar shows the incidence of macroscopic sarcoma, and blue bar shows the incidence of microscopic sarcoma. i iPSC derivation from an independent sarcoma cell line (K11). A higher incidence and shorter latency of secondary sarcoma development were observed in sarcoma (K11)-iPSC mice within 2 weeks. Scale bars: 600 µm (left upper), 300 µm (left lower), 200 µm (right upper), and 50 µm (right lower)